Research programme: growth factor receptor antagonists - Kyowa Hakko/Millennium

Drug Profile

Research programme: growth factor receptor antagonists - Kyowa Hakko/Millennium

Latest Information Update: 19 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko; Millennium Pharmaceuticals
  • Developer Millennium Pharmaceuticals
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 16 Dec 2003 No development reported - Preclinical for Reperfusion injury in USA (unspecified route)
  • 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
  • 17 Apr 1998 Preclinical development for Reperfusion injury in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top